In patients with prostate cancer, what is the uptake in tumours and normal tissue on positron emission tomography (PET) following administration of Ga-68 THP-PSMA?

Trial Profile

In patients with prostate cancer, what is the uptake in tumours and normal tissue on positron emission tomography (PET) following administration of Ga-68 THP-PSMA?

Completed
Phase of Trial: Phase 0

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Gallium 68 THP PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Diagnostic use
  • Most Recent Events

    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top